San Diego, California--(Newsfile Corp. - November 24, 2025) - Skye Bioscience, Inc. (NASDAQ: SKYE) ("Skye"), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will participate in the following upcoming investment conferences:
Citi Global Healthcare Conference (Miami)
1x1 meetings: Dec. 2
Evercore Annual Healthcare Conference (Coral Gables)
Fireside Chat: Dec. 3, 12:55 pm ET
1x1 meetings
Piper Sandler Annual Healthcare Conference (New York)
Fireside Chat: Dec. 4, 11:30 am ET
1x1 meetings
Available webcasts will be accessible on Skye's website.
About Skye Bioscience
Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of potential first-in-class therapeutics with potential clinical and commercial differentiation. Skye is conducting a Phase 2a clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: www.skyebioscience.com. Connect with us on X and LinkedIn.
CONTACTS
Investor & Media Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
(858) 410-0266
LifeSci Advisors, Mike Moyer
This email address is being protected from spambots. You need JavaScript enabled to view it.
(617) 308-4306
| Last Trade: | US$1.12 |
| Daily Change: | -0.09 -7.44 |
| Daily Volume: | 756,944 |
| Market Cap: | US$35.910M |
November 05, 2025 October 06, 2025 September 19, 2025 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
